Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data The research demonstrated that treatment with FT011 results in a remarkable reversal in the activation of genetic markers associated with fibrosis Fibrosis is responsible for 45 percent of all deaths globally - FT011 is a novel drug with potential to treat chronic fibrosis in multiple organs such as the kidneys, skin, lungs, heart, and eyes Certa Therapeutics is a clinical stage biotechnology company based in Melbourne, Australia, developing innovative therapies for the treatment of fibrotic diseases ANN ARBOR, Mich., Nov. 4, 2022 /PRNewswire/ New research presented today by the University of Michigan reveals ground-breaking results for Certa Therapeutics' FT011, a novel potential treatment of serious inflammatory and fibrotic diseases. The results in a chronic kid
Research presented today by University of Michigan Medical School highlights FT011 s ground-breaking treatment potential from human expression profiles in.
Certa Therapeutics investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.